JPMorgan raises Moderna stock price target on expense outlook
JPMorgan has increased its price target for Moderna Inc. (NASDAQ:MRNA) to $102 from $77, while keeping an Underweight rating on the stock. This adjustment comes after Moderna's analyst day, updated 2026 guidance, and its 2027 and beyond expense framework. The firm views the expense outlook as a balance of optimism and conservatism, citing incremental investment in oncology following the first phase III success of intismeran.
A healthier cash balance at Moderna also supports this investment. The next important event for the stock, according to JPMorgan, is the interim results for intismeran's randomized phase II trial in adjuvant RCC, which could arrive in late 2026 or early 2027, with a reasonably good probability of success. Despite raising the price target, JPMorgan's valuation concerns remain, with the firm seeing a substantial gap between Moderna's current market cap of $87.1 billion and what can be reasonably justified for the pipeline, aligning with InvestingPro analysis that Moderna is currently overvalued.
Moderna reported a profit in Q3 2026, with earnings of $0.38 per share, up from a loss in the same period last year, and revenue rising 29% year-over-year to $1.3 billion. Piper Sandler raised its price target for Moderna to $305 from $230, maintaining an Overweight rating, based on Moderna's third-quarter product sales of $1.27 billion and its revised 2026 revenue guidance of 15-25% growth.
Additionally, Moderna reduced interest rates on its loans, lowering borrowing costs through its Credit and Guaranty Agreement with Ares Capital Corporation. Moderna's Chief Legal Officer, Shannon Thyme Klinger, will retire at the end of March 2027, continuing to be with the company until then to facilitate a smooth transition of her responsibilities.
Written by urgent.news from Investing.com's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.